CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC

Biochemical and Biophysical Research Communications

Volumn 419, Issue 4, 2012, Pages 612-616

  Congrains, Ada ^a   Kamide, Kei ^a   Katsuya, Tomohiro ^a   Yasuda, Osamu ^b   Oguro, Ryousuke ^a   Yamamoto, Koichi ^a   Ohishi, Mitsuru ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

9p21 Locus; ANRIL; Atherosclerosis; CDKN2BAS; VSMC

Indexed keywords

ALPHA INTEGRIN; ANRIL PROTEIN; BCL2 RELATED PROTEIN A1; COLLAGEN TYPE 3; COLONY STIMULATING FACTOR 1; ELASTIN; FIBROBLAST GROWTH FACTOR; INHIBITOR OF APOPTOSIS PROTEIN 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; OSTEOPONTIN; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SMALL INTERFERING RNA; STROMELYSIN; TENASCIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VASCULAR ENDOTHELIAL CADHERIN;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; EXON; GENE EXPRESSION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, UNTRANSLATED;

EID: 84863421652     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.050     Document Type: Article

References (44)

1. The Wellcome Trust Case Control Consortium, Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls, Nature 2007, 447, 661-678.
2. Broadbent H.M., Peden J.F., Lorkowski S., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked, SNPs in the ANRIL locus on chromosome 9p. Hum. Mol. Genet. 2008, 17(6):806-814.
3. Helgadottir A., Thorleifsson G., Magnusson K.P., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 2008, 40(2):217-224.
4. Gschwendtner A., Bevan S., Cole J.W., Plourde A., et al. International stroke genetics consortium. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann. Neurol. 2009, 65(5):531-539.
5. Yang X.R., Liang X., Pfeiffer R.M., et al. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Familial Cancer 2010, 9(4):625-633.
6. Falchi M., Bataille V., Hayward N.K., et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat. Genet. 2009, 41(8):915-919. Epub. 2009 Jul. 5.
7. Sherborne A.L., Hosking F.J., Prasad R.B., et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 2010, 42(6):492-494.
8. D. Cugino, F. Gianfagna, I. Santimone et al., Type 2 diabetes and polymorphisms on chromosome 9p21: A meta-analysis, Nutrition, Metabolism and Cardiovascular Diseases, (in Press), doi:10.1016/j.numecd.2010.11.010.
9. Schaefer A.S., Richter G.M., Groessner-Schreiber B., et al. Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. PLoS Genet. 2009, 5(2):e1000378. 10.1371/ journal.pgen.1000378.
10. Ernst F.D., Uhr K., Teumer A., et al. Replication of the association of chromosomal region 9p21.3 with generalized aggressive periodontitis (gAgP) using an independent case-control cohort. BMC Med. Genet. 2010, 11:119. 10.1186/1471-2350-11-119.
11. Yu J.T., Yu Y., Zhang W., et al. Single nucleotide polymorphism rs1333049 on chromosome 9p21.3 is associated with Alzheimer's disease in Han Chinese. Clin. Chim. Acta. 2010, 411(17-18):1204-1207. Epub. 2010 Apr 26.
12. E. Emanuele, S. Lista, R. Ghidoni et al., Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease, Neurobiol. Aging. 2009 [Epub ahead of print]. doi: 10.1016/j.neurobiolaging 2009.07.003.
13. Uno S., Zembutsu H., Hirasawa A., et al. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat. Gent. 2010, 42:707-710.
14. Melzer D., Frayling T.M., Murray A., et al. A common variant of the p16INK4a genetic region is associated with physical function in older people. Mechanisms of Ageing and Development 2007, 128(5-6):370-377.
15. Burdon K.P., Macgregor S., Hewitt A.W., et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet. 2011, 43(6):574-578.
16. Ramdas D.W., van Koolwijk M.L., Lemij H.G., et al. Common genetic variants associated with open-angle glaucoma. Hum. Mol. Genet. 2011, 20(12):2464-2471.
17. Yap K.L., Li S., Muñoz-Cabello A.M., et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Molecular Cell. 2010, 38(5):662-674.
18. Kotake Y., Nakagawa T., Kitagawa K., et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2011, 30:1956-1962.
19. A. Congrains, K. Kamide, R. Oguro et al., Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B, Atherosclerosis, (in press), doi:10.1016/j.atherosclerosis.2011.11.017.
20. Sato K., Nakagawa H., Tajima A., et al. ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol. Rep. 2010, 24(3):701-707.
21. Pasmant E., Laurendeau I., Héron D., et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 2007, 67:3963.
22. L. Folkersen, T. Kyriakou, A. Goel et al., Relationship between CAD Risk Genotype in the Chromosome 9p21 Locus and Gene Expression. Identification of Eight New ANRIL Splice Variants, PLoS ONE 4 (11) e7677. doi:10.1371/journal.pone.0007677.
23. O. Jarinova, A F.R. Stewart, R. Roberts et al., Functional Analysis of the Chromosome 9p21.3 Coronary Artery Disease Risk Locus, Arterioscler. Thromb. Vasc. Biol. (2009), doi:10.1161/ATVBAHA.109.189522.
24. Holdt L.M., Beutner F., Scholz M., et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler. Thromb Vasc. Biol. 2010, 10.1161/ATVBAHA.109.196832.
25. Thomadaki H., Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications. Cancer 2006, 43(1):1-67. 10.1080/10408360500295626.
26. Resink T.J., Philippova M., Joshi M.B., et al. Cadherins and cardiovascular disease. Swiss Med. Wkly. 2009, 139(9-10):122-134.
27. George S.J., Dwivedi A. MMPs, cadherins, and cell proliferation. Trends Cardiovasc. Med. 2004, 14(3):100-105.
28. Raab G., Klagsbrun M. Heparin-binding EGF-like growth factor. Biochimica et Biophysica Acta (BBA) - Reviews on. Cancer 1997, 1333(3):F179-F199.
29. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler., Thromb., Vasc. Biol. 2007, 27:2302-2309.
30. Irvine K.M., Andrews M.R., Fernandez-Rojo M.A., et al. Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages. J. Leukocyte Biol. 2009, 85(2):278-328.
31. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-B, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1591-1598.
32. Pechlivanis S., Scherag A., Mühleisen T.W., et al. Coronary artery calcification and its relationship to validated genetic variants for diabetes mellitus assessed in the heinz nixdorf recall cohort. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1867-1872.
33. Samarakoon R., Higgins P.J. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost. 2008, 6:976-983.
34. Al-Fakhri N., Chavakis T., Schmidt-Wöll T., et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol. Chem. 2003, 384(3):423-435.
35. Ongusaha P.P., Kwak J.C., Zwible A.J., et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 2004, 64:5283.
36. Pitsos M., Kanakas N. The role of matrix metalloproteinases in the pathogenesis of endometriosis. Reprod. Sci. 2009, 16(8):717-726.
37. Kaku M., Tsutsui K., Motokawa M., et al. Amyloid β protein deposition and neuron loss in osteopetrotic (op/op) mice. Brain Res. Protoc. 2003, 12(2):104-108.
38. Rinn J.L., Kertesz M., Wang J.K., et al. Functional demarcation of active and silent chromatin domains in human hox loci by noncoding RNAs. Cell 2007, 129(7):1311-1323.
39. L. Li, T. Feng, Y. Lian et al., Role of human noncoding RNAs in the control of tumorigenesis, PNAS (2009) (published ahead of print July 22, 2009), doi:10.1073/pnas.0906005106.
40. Paul A., Hung-Junn Chang B., Li L., et al. Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circulation Research 2008, 102:1492-1501.
41. Brooke B.S., Bayes-Genis A., Li D.Y. New insights into elastin andvasculardisease. Trends Cardiovasc. Med. 2003, 13(5):176-181.
42. Segev A., Aviezer D., Safran M., et al. Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist. Cardiovasc. Res. 2002, 53(1):232-241.
43. Graham T.L., Mookherjee C. Suckling KE, et al. The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice. Atherosclerosis 2005, 181(1):29-37.
44. Wallner K., Li C., Shah P.K., et al. EGF-like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler., Thromb., Vasc. Biol. 2004, 24:1416-1421.